Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Non-Current Assets readings, the most recent being $231.1 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 5.06% to $231.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $945.2 million, a 3.31% decrease, with the full-year FY2025 number at $236.5 million, down 4.94% from a year prior.
  • Non-Current Assets hit $231.1 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $236.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $250.0 million in Q4 2023 to a low of $30.6 million in Q2 2022.
  • Median Non-Current Assets over the past 5 years was $236.8 million (2025), compared with a mean of $211.5 million.
  • Biggest five-year swings in Non-Current Assets: fell 10.93% in 2022 and later surged 677.77% in 2023.
  • Kiniksa Pharmaceuticals International's Non-Current Assets stood at $216.6 million in 2022, then grew by 15.43% to $250.0 million in 2023, then fell by 0.51% to $248.8 million in 2024, then fell by 4.94% to $236.5 million in 2025, then decreased by 2.26% to $231.1 million in 2026.
  • The last three reported values for Non-Current Assets were $231.1 million (Q1 2026), $236.5 million (Q4 2025), and $236.8 million (Q3 2025) per Business Quant data.